Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAtla, Inc. stock logo
BCAB
BioAtla
$0.33
-8.1%
$0.40
$0.24
$2.53
$20.98M0.9791,629 shs492,189 shs
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
$1.64
-4.1%
$1.76
$1.20
$3.35
$5.35M0.79108,881 shs236,838 shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$2.00
-9.9%
$1.87
$1.35
$53.79
$27.08MN/A3.80 million shs291,573 shs
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$0.53
-1.4%
$0.54
$0.39
$3.75
$33.87M-0.024.68 million shs605,022 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAtla, Inc. stock logo
BCAB
BioAtla
-8.10%-6.99%-17.02%-40.86%-81.77%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
-4.09%-13.87%-6.02%-14.14%-91.72%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-9.91%-9.50%+38.89%+21.95%-94.75%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-1.40%-0.68%-0.64%-51.07%-81.33%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioAtla, Inc. stock logo
BCAB
BioAtla
2.0695 of 5 stars
3.31.00.00.02.22.50.6
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
1.4406 of 5 stars
3.12.00.00.00.01.70.6
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
1.757 of 5 stars
3.51.00.00.01.11.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioAtla, Inc. stock logo
BCAB
BioAtla
2.50
Moderate Buy$5.001,415.15% Upside
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
0.00
N/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.25
Hold$12.17508.33% Upside
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
3.00
Buy$7.331,287.84% Upside

Current Analyst Ratings Breakdown

Latest CPHI, BCAB, QTTB, and RANI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$14.00 ➝ $4.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioAtla, Inc. stock logo
BCAB
BioAtla
$11M1.75N/AN/A$0.25 per share1.32
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
$4.30M1.25N/AN/A$0.70 per share2.34
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$1.16M21.03N/AN/A$0.47 per share4.26
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$1.20M27.83N/AN/A$0.06 per share8.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioAtla, Inc. stock logo
BCAB
BioAtla
-$69.78M-$1.22N/AN/AN/AN/A-373.47%-116.55%8/6/2025 (Estimated)
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
-$3.08MN/A0.00N/A-85.56%-63.93%-31.42%N/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$47.73M-$4.94N/AN/AN/AN/A-447.33%-59.77%8/6/2025 (Estimated)
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$30.02M-$0.99N/AN/AN/AN/A-1,258.76%-80.52%8/5/2025 (Estimated)

Latest CPHI, BCAB, QTTB, and RANI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
BioAtla, Inc. stock logo
BCAB
BioAtla
-$0.29N/AN/AN/AN/AN/A
8/14/2025Q2 2025
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$1.14N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.19N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.22-$0.22N/A-$0.22N/A$0.20 million
5/8/2025Q1 2025
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$1.23-$0.90+$0.33-$0.90N/AN/A
5/6/2025Q1 2025
BioAtla, Inc. stock logo
BCAB
BioAtla
-$0.28-$0.29-$0.01-$0.26N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioAtla, Inc. stock logo
BCAB
BioAtla
N/AN/AN/AN/AN/A
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
N/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/AN/AN/AN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioAtla, Inc. stock logo
BCAB
BioAtla
N/A
2.35
2.35
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
0.22
0.79
0.26
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
1.68
4.71
4.71
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
2.75
0.88
0.88

Institutional Ownership

CompanyInstitutional Ownership
BioAtla, Inc. stock logo
BCAB
BioAtla
77.23%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
N/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
31.32%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
30.19%

Insider Ownership

CompanyInsider Ownership
BioAtla, Inc. stock logo
BCAB
BioAtla
11.50%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
17.32%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
40.00%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
45.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioAtla, Inc. stock logo
BCAB
BioAtla
6058.42 million51.70 millionOptionable
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
2503.26 million15.92 millionNot Optionable
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
3912.20 million7.32 millionN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
11063.21 million34.71 millionOptionable

Recent News About These Companies

Rani Therapeutics Holdings, Inc. (RANI) - Yahoo Finance
Rani Therapeutics strikes deal to issue new warrants
RANI: 1Q:25 Financial Results
Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)
Rani Therapeutics management to meet virtually with Lake Street
RANI: 2024 Financial Results
Q4 2024 Rani Therapeutics Holdings Inc Earnings Call
Rani Therapeutics reports Q4 EPS (27c), consensus (23c)

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioAtla stock logo

BioAtla NASDAQ:BCAB

$0.33 -0.03 (-8.10%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.34 +0.01 (+2.73%)
As of 08/1/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

China Pharma stock logo

China Pharma NYSE:CPHI

$1.64 -0.07 (-4.09%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$1.66 +0.02 (+1.28%)
As of 08/1/2025 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Q32 Bio stock logo

Q32 Bio NASDAQ:QTTB

$2.00 -0.22 (-9.91%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.99 -0.01 (-0.50%)
As of 08/1/2025 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Rani Therapeutics stock logo

Rani Therapeutics NASDAQ:RANI

$0.53 -0.01 (-1.40%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.51 -0.02 (-3.48%)
As of 08/1/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.